Therapeutic Potential of Morin in Reducing Somatic Cell Counts and Clinical Scores in Bovine Mastitis Caused by Escherichia coli and Streptococcus uberis

Marcin Kocik, Artur Burmańczuk (), Michał Bednarski, Marta Sołtysiuk, Tomasz Grabowski and Ewa Tomaszewska
Additional contact information
Marcin Kocik: Private Veterinary Practice, Chopina 5, 33-100 Tarnów, Poland
Artur Burmańczuk: Department of Pharmacology, Toxicology and Environmental Protection, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland
Michał Bednarski: Department of Epizootiology and Clinic of Bird and Exotic Animals, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Grunwaldzki Sq. 47, 50-366 Wroclaw, Poland
Marta Sołtysiuk: Department of Veterinary Public Health, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 2, 10-917 Olsztyn, Poland
Tomasz Grabowski: Department of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdansk, Gen. J. Hallera 107, 80-416 Gdańsk, Poland
Ewa Tomaszewska: Department Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland

Agriculture, 2025, vol. 15, issue 22, 1-15

Abstract: Mastitis caused by Escherichia coli and Streptococcus uberis remains one of the leading causes of antimicrobial use in dairy cattle, contributing to resistance development and economic losses. This study evaluated the therapeutic potential of the natural flavonoid morin in clinical mastitis in dairy cows. The in vitro antimicrobial activity of morin (1–3% w / v ) was assessed by disk diffusion, and the 3% formulation was selected for an in vivo field trial. Seventy-two Holstein–Friesian cows with mastitis caused by E. coli or S. uberis were randomly assigned to one of three intramammary treatments: 3% morin, phosphate-buffered saline, or an antibiotic, serving as a positive control. Somatic cell count (SCC) and clinical scores were monitored for seven days. In E. coli infections, morin significantly reduced somatic cell scores at 144 h and 168 h and improved clinical scores from 48 h onward, showing efficacy comparable to antibiotics. In S. uberis mastitis, morin induced clinical improvement at 96–168 h but resulted in slower and smaller SCC reduction than antibiotic control therapy. Phosphate-buffered saline produced no significant changes. These results indicate that morin exerts anti-inflammatory and supportive effects in bovine mastitis, particularly in Gram-negative infections, but is less effective against S. uberis . Further studies on pharmacokinetics, bacteriological cure rates, and optimized formulations are warranted to confirm its clinical utility.

Keywords: morin; mastitis; intramammary; E. coli; S. uberis (search for similar items in EconPapers)
JEL-codes: Q1 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2077-0472/15/22/2359/pdf (application/pdf)
https://www.mdpi.com/2077-0472/15/22/2359/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jagris:v:15:y:2025:i:22:p:2359-:d:1794143

Access Statistics for this article

Agriculture is currently edited by Ms. Leda Xuan

More articles in Agriculture from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().